Previous 10 | Next 10 |
home / stock / tbpmf / tbpmf news
Tetra Bio-Pharma Inc. Announces Changes to its Board of Directors and the Filing of a Supplement to its Management Information Circular Canada NewsWire OTTAWA, ON , May 18, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc . (" Tetra " or the " Company ")...
NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “...
First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or t...
Tetra Bio-Pharma Announces $10 Million "Bought Deal" Public Offering Canada NewsWire /NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO , May 10, 2021 /CNW/ - Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TB...
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “...
First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 6, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:T...
This Definitive Agreement is expected to generate an excess of $ 47,5M CAD in revenue for Tetra OTTAWA, ON / ACCESSWIRE / May 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) ( FSE:JAM1 ) , a leader in cannabinoid-derived drug discovery ...
A first of its kind synthetic cannabinoid medication to manage eye pain in the veterinary setting OTTAWA, ON / ACCESSWIRE / May 4, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) , a biopharmaceutical pioneer in immunomodulator drug disc...
The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License OTTAWA, ON / ACCESSWIRE / May 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) , a leader in cann...
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor ȁ...
News, Short Squeeze, Breakout and More Instantly...
Tetra Bio-Pharma Inc Company Name:
TBPMF Stock Symbol:
OTCMKTS Market:
Tetra Bio-Pharma Inc Website:
(TheNewswire) Montreal – TheNewswire - August 1, 2023 – Tetra Bio-Pharma Inc. (“ Tetra ” or the “ Company ”) ( TSX:TBP ) ( OTC:TBPMF ) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced that...
(TheNewswire) MONTREAL, QUEBEC – TheNewswire – May 11, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, today announced it has cancelled its New Drug Subm...
(TheNewswire) Montreal, QC - TheNewswire - March 10, 2023 - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) , a leader in cannabinoid-derived drug discovery and development is pleased to announce Health Canada h...